ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer

Du, Fenqi; Liu, Yanlong*哈尔滨医科大学
Journal of Clinical Laboratory Analysis2022-1DOI: 10.1002/jcla.24141
9被引9阅读
引用收藏
分享

摘要

Colorectal cancer is one of the most common malignant tumors and, hence, has become one of the most important public health issues in the world. Treatment with immune checkpoint inhibitors (ICIs) successfully improves the survival rate of patients with melanoma, non-small-cell lung cancer, and other malignancies, and its application in metastatic colorectal cancer is being actively explored. However, a few patients develop drug resistance. Predictive molecular markers are important tools to precisely screen patient groups that can benefit from treatment with ICIs. The current article focused on certain important predictive molecular markers for ICI treatment in colorectal cancer, including not only some of the mature molecular markers, such as deficient mismatch repair (d-MMR), microsatellite instability-high (MSI-H), tumor mutational burden (TMB), programmed death-ligand-1 (PD-L1), tumor immune microenvironment (TiME), and tumor-infiltrating lymphocytes (TILs), but also some of the novel molecular markers, such as DNA polymerase epsilon (POLE), polymerase delta 1 (POLD1), circulating tumor DNA (ctDNA), and consensus molecular subtypes (CMS). We have reviewed these markers in-depth and presented the results from certain important studies, which suggest their applicability in CRC and indicate their advantages and disadvantages. We hope this article is helpful for clinicians and researchers to systematically understand these markers and can guide the treatment of colorectal cancer.

学科与关键词

关键词
colorectal cancerimmune checkpoint inhibitorsimmunotherapymolecular markers
相关
加载中…
  • How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
    Wang, Qianyu; Shen, Xiaofei; Chen, Gang*; Du, Junfeng*International Journal of Cancer, 2023, 153(4): 709-722.被引 1
  • Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy
    Bai, Ziyi; Zhou, Yao; Ye, Zifan; Xiong, Jialong; Lan, Hongying; Wang, Feng*Frontiers in Immunology, 2022, 12: 808964.被引 49
  • DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden
    Huang, Hao; Cao, Weifan; Long, Zhiping; Kuang, Lei; Li, Xi; Feng, Yifei; Wu, Yuying; Zhao, Yang; Chen, Yinggang; Sun, Peng; Peng, Panxin; Zhang, Jinli; Yuan, Lijun; Li, Tianze; Hu, Huifang; Li, Gairui; Yang, Longkun; Zhang, Xing; Hu, Fulan*; Sun, Xizhuo*; Hu, Dongsheng*Frontiers in Oncology, 2023, 12: 1030335.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Clinical Laboratory Analysis
发表日期
2022-01
卷期
第 36 卷, 第 1 期
页码
e24141
DOI
10.1002/jcla.24141
语言
ENGLISH
期刊等级
4区
成果收录
SCIE

作者

  • D

    Du, Fenqi (第一作者)

    harbin med univ

  • L

    Liu, Yanlong (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417